OPINION (COM(2025)0102) – C100048/2025 – 2025/0102(COD))
On the proposal for a regulation of the European Parliament and of the Council laying a framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest, and amending Regulation (EU) 2024/795
IMCO-AD-776854
Committee on the Internal Market and Consumer Protection · Rapporteur: Marion Walsmann
✦ In short · AI summary of this text, generated 4 Sept 2026
Written by a language model from the full text only; every figure comes from the text. The paragraph links open the paragraph a statement rests on — check the text itself before relying on it.
The committee opinion on the Critical Medicines Act proposes amendments to strengthen procurement, joint procurement, sustainability criteria, and the European preference system.¶¶¶
Committee position. The committee proposes amendments focusing on four priorities: reforming procurement, strengthening joint procurement, clarifying sustainability criteria, and designing a WTO-compatible European preference system.¶¶¶
Key points
- Calls for procurement procedures to prioritise security of supply, stability of deliveries and fair competition over lowest price, with flexibility for multi-winner procedures and exemptions for orphan medicines.¶
- Urges streamlining of joint procurement provisions to avoid duplication and ensure coherence with existing tools, benefiting smaller Member States.¶
- Requires a systematic assessment of interactions between sustainability criteria and security of supply to prevent conflicts.¶
- Supports a European preference system designed to be WTO-compatible and incentive-based, avoiding protectionism.¶